Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 627.00 GBp
Change Today +15.00 / 2.45%
Volume 194.6K
As of 11:35 AM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

gw pharmaceuticals plc (GWP) Snapshot

Open
614.00 GBp
Previous Close
612.00 GBp
Day High
631.00 GBp
Day Low
607.50 GBp
52 Week High
04/27/15 - 697.00 GBp
52 Week Low
10/16/14 - 299.50 GBp
Market Cap
1.6B
Average Volume 10 Days
233.3K
EPS TTM
-0.07 GBp
Shares Outstanding
256.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for GW PHARMACEUTICALS PLC (GWP)

gw pharmaceuticals plc (GWP) Details

GW Pharmaceuticals plc, a biopharmaceutical company, together with its subsidiaries, engages in discovering, developing, and commercializing cannabinoid prescription medicines. It operates in three segments: Commercial, Sativex Research and Development, and Pipeline Research and Development. The company primarily offers Sativex, an oromucosal spray for the treatment of multiple sclerosis symptoms, cancer pain, and neuropathic pain. It also focuses on the Phase III clinical development program of Sativex for use in the treatment of cancer pain. In addition, the company’s product pipeline includes an orphan childhood epilepsy program, as well as other product candidates in Phase I and II clinical development for the treatment of glioma, ulcerative colitis, type-2 diabetes, and schizophrenia. It has a strategic alliance with Otsuka Pharmaceutical Co., Ltd. The company operates in the United Kingdom, Europe, the United States, Canada, and Asia. GW Pharmaceuticals plc was founded in 1998 and is based in Salisbury, the United Kingdom.

320 Employees
Last Reported Date: 05/11/15
Founded in 1998

gw pharmaceuticals plc (GWP) Top Compensated Officers

Chief Executive Officer, Managing Director an...
Total Annual Compensation: 567.8K GBP
Founder, Executive Chairman and Chairman of N...
Total Annual Compensation: 696.1K GBP
Chief Financial Officer, Company Secretary an...
Total Annual Compensation: 389.8K GBP
Chief Operating Officer and Executive Directo...
Total Annual Compensation: 421.8K GBP
Research & Development Director and Executive...
Total Annual Compensation: 475.3K GBP
Compensation as of Fiscal Year 2014.

gw pharmaceuticals plc (GWP) Key Developments

GW Pharmaceuticals plc Appoints Julian Gangolli as President, North America; to Expand its UK Manufacturing and R&D Operations

GW Pharmaceuticals plc announced that the company has appointed Julian Gangolli as President, North America and is also relocating its Chief Executive Officer, Justin Gover, to the United States. Mr. Gangolli was, from 2004 until April 2015, President of the North American Pharmaceutical division of Allergan Inc, with responsibility for a 1,400-person integrated commercial operation with sales exceeding $3.8 billion in 2014. Mr. Gangolli was an integral part of the executive management team that transformed Allergan into one of the leading specialty pharmaceutical companies in the U.S. Mr. Gangolli will join the company in June and is expected to be appointed to the company's board of directors. As President, North America Pharmaceuticals, Mr. Gangolli's responsibilities represented over 50% of Allergan's revenue, 60% of its profit, and over 60% of its year-on-year profit growth. He was responsible for four business units supporting each of the specialty areas of Ophthalmology/Optometry (Eye Care), Neurosciences, Urology and Medical Dermatology for the U.S. and Canada, each of which are considered category leaders in their respective therapeutic areas. In addition to his commercial responsibilities, Mr. Gangolli had responsibility for strategic planning, business development, research and product development planning for the North American division. Prior to his role as President, North America, Mr. Gangolli was Senior Vice President, U.S. Eye Care, at Allergan from 1998 to 2004. The company is also continuing to expand its UK manufacturing and R&D operations in preparation for future commercialization as well as pipeline development.

GW Pharmaceuticals plc Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-12-2015 04:20 PM

GW Pharmaceuticals plc Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-12-2015 04:20 PM. Venue: Encore at the Wynn, 3131 S Las Vegas Blvd, Las Vegas, Nevada, United States. Speakers: Justin D. Gover, Chief Executive Officer, Managing Director and Executive Director.

GW Pharmaceuticals Initiates Phase 3 Pivotal Study of Epidiolex(R) (CBD) in Lennox-Gastaut Syndrome

GW Pharmaceuticals plc announced that it has commenced a phase 3 clinical trial of Epidiolex® (cannabidiol or CBD) for the treatment of Lennox-Gastaut syndrome (LGS), a rare and severe form of childhood-onset epilepsy. During 2014, GW received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for Epidiolex for the treatment of LGS. GW anticipates that top-line data from this trial will be available in early 2016. This phase 3 pivotal trial is a randomized, double-blind, 14-week comparison of Epidiolex versus placebo in a total of 150 patients to assess the dose-ranging safety and efficacy of Epidiolex as an adjunctive antiepileptic treatment. The treatment period will consist of a two-week titration period followed by a 12-week maintenance period. This phase 3 trial will have three arms of 50 patients; 20mg/kg and 10mg/kg of Epidiolex and placebo. The primary measure of this trial will be the percentage change from baseline in number of drop seizures in patients taking Epidiolex versus placebo. Several additional efficacy and safety secondary outcome measures will be analysed. Following their participation in the study, all patients are eligible to receive Epidiolex under a long term open label extension study. LGS usually begins before 4 years of age, and can be caused by a number of conditions, including brain malformations, severe head injuries, central nervous system infections, and inherited degenerative or metabolic conditions. In 30% to 35% of patients, no cause can be found. Patients commonly have frequent seizures of a wide variety, including convulsive, atonic seizures (brief loss of muscle tone and consciousness, causing abrupt falls). Drug resistance is one of the main features of LGS. Most children with LGS experience some degree of impaired intellectual functioning or information processing, as well as developmental delays and behavioral disturbances. It is estimated that there are approximately 14,000-18,500 patients with LGS in the United States and 23,000-31,000 patients with LGS in Europe.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GWP:LN 627.00 GBp +15.00

GWP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cannabis Science Inc $0.03 USD +0.0014
Medical Marijuana Inc $0.09 USD +0.0018
PharmaCyte Biotech Inc $0.16 USD +0.0025
View Industry Companies
 

Industry Analysis

GWP

Industry Average

Valuation GWP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 53.5x
Price/Book 10.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 58.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GW PHARMACEUTICALS PLC, please visit www.gwpharm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.